Alibaba Health Information Technology : RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JULY 30, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿 里 健 康 信 息 技 術 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

RESULTS OF THE ANNUAL GENERAL MEETING

HELD ON JULY 30, 2020

The board (the ''Board'') of directors (the ''Directors'') of Alibaba Health Information Technology Limited (the ''Company'', together with its subsidiaries, the ''Group'') is pleased to announce that, on July 30, 2020, the Company held its Annual General Meeting (the ''AGM'') at which all resolutions set out in the notice of the AGM dated June 30, 2020 (the ''Notice'') were duly passed by way of poll.

Reference is made to the circular (the ''Circular'') of the Company dated June 30, 2020. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

- 1 -

RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held at Holiday Inn Express Hong Kong Causeway Bay, Meeting Room I & II, 7/F, 33 Sharp Street East, Causeway Bay, Hong Kong on Thursday, July 30, 2020 at 10 : 30 a.m., all the ordinary resolutions and special resolution set out in the Notice (the ''Resolutions'') were duly passed by way of poll at the AGM. The poll results in respect of the Resolutions were as follows:

	ORDINARY RESOLUTIONS		Number of Shares Voted (%)
	For	Against
1.	To receive,	consider	and adopt	the	audited	9,360,172,324	3
	consolidated financial statements of the Company	(99.99%)	(0.01%)
	and its subsidiaries and the reports of the directors
	and auditor for the year ended March 31, 2020.
2.	(a) To re-elect the following retiring directors of
	the Company:
	(i) Mr.	ZHU	Shunyan as	an	executive	9,169,285,509	193,270,818
	director of the Company;			(97.94%)	(2.06%)
	(ii) Mr. WANG Qiang as an executive	9,328,875,207	33,681,120
	director of the Company; and		(99.64%)	(0.36%)
	(iii) Mr. WU Yongming as a non-executive	9,314,663,428	48,788,899
	director of the Company.			(99.48%)	(0.52%)
	(b) To authorize the board (the ''Board'') of	9,357,352,587	4,749,740
	directors (the ''Directors'') of the Company to	(99.95%)	(0.05%)
	fix the Directors' remuneration.
3.	To re-appoint Ernst & Young as the auditor of the	9,328,345,956	35,106,371
	Company and to authorize the Board to fix its	(99.63%)	(0.37%)
	remuneration.
4.	To grant a general mandate to the Directors to	8,714,560,489	647,541,838
	issue and allot shares.				(93.08%)	(6.92%)
5.	To grant a general mandate to the Directors to	9,357,131,527	4,970,800
	repurchase shares.				(99.95%)	(0.05%)
6.	To approve the addition of the aggregate amount of	8,716,154,489	647,297,838
	shares repurchased as mentioned in ordinary	(93.09%)	(6.91%)
	resolution no. 5 to the aggregate amount that may
	be issued and allotted pursuant to ordinary
	resolution no. 4.

- 2 -

	ORDINARY RESOLUTIONS	Number of Shares Voted (%)
For	Against
7.	To approve the grant of a mandate authorizing the	8,926,066,946	437,385,381
	Directors to grant awards of options and/or	(95.33%)	(4.67%)
	restricted share units (the ''RSUs'') pursuant to
	the share award scheme adopted by the Company
	on November 24, 2014 (the ''Share Award Scheme'')
	in respect of a maximum number of the underlying
	new shares that is equivalent to 3 per cent. of the
	shares in issue as at the date of passing of this
	resolution during the period from the date of
	passing this resolution until the earlier of (a) the
	conclusion of the Company's next annual general
	meeting, (b) the end of the period within which the
	Company is required by any applicable law or its
	bye-laws to hold its next annual general meeting,
	and (c) the date on which this resolution is varied
	or revoked by an ordinary resolution of the
	shareholders of the Company in general meeting
	(the ''Applicable Period'') and to allot, issue and
	deal with shares underlying the options and/or
	RSUs granted pursuant to the Share Award Scheme
	during the Applicable Period as and when such
	options and/or RSUs vest.
	SPECIAL RESOLUTION	For	Against
8.	To approve and adopt the new bye-laws of the	9,276,803,341	85,748,986
	Company as the bye-laws of the Company in	(99.08%)	(0.92%)
	substitution for, and to the exclusion of, the
	existing bye-laws of the Company with immediate
	effect after the close of the Meeting and that any
	Director or company secretary of the Company be
	authorized to do all things necessary to implement
	the adoption of the new bye-laws of the Company.

- 3 -

Notes:

1. The full text of the Resolutions is set out in the Notice.
2. As at the date of the AGM:
3. 1. the total number of Shares in issue was 12,951,582,924. Since the last next day disclosure return submitted by the Company under Rule 13.25A(1) of the Listing Rules on July 21, 2020, the Company had issued a total of 76,750 Shares due to the exercise of share options by certain employees under the Company's share award scheme. Such share options were not exercised by a Director and hence a further next day disclosure return was not submitted by the Company under Rule 13.25A(1) of the Listing Rules;
   2. a total of 482 grantees under the Share Award Scheme held 113,704,585 Shares (which represented approximately 0.88% of the total issued Shares as at the date of the AGM) upon exercising and vesting of the Options and the RSUs (as applicable). Such grantees included, among others, (i) one Director, namely Mr. Zhu Shunyan, who was interested in 3,400,000 Shares as a result of the exercising and vesting of Options and RSUs granted to him, (ii) one Director, namely Mr. Wang Qiang, who was interested in 3,534,250 Shares as a result of exercising and vesting of Options and RSUs granted to him, (iii) one Director, namely Mr. Wang Lei, who was interested in 1,213,500 Shares as a result of the exercising and vesting of Options and RSUs granted to him, and (iv) other directors of the subsidiaries of the Company, who were interested in 10,797,821 Shares in total as a result of the exercising and vesting of Options and RSUs (as applicable) granted to them. All such 482 grantees abstained from voting on Resolution no. 7 in relation to the 2020 Share Award Mandate. Except as disclosed herein and the extent that the Directors were aware of and having made all reasonable enquiries, none of the Directors and directors of the Company's subsidiaries, who were also Participants under the Share Award Scheme who had been granted any Share Awards, held any Share;
   3. the total number of shares entitling the Shareholders to attend and vote for or against the Resolutions (other than Resolution no.7) at the AGM was 12,951,521,174 and the total number of share entitling the Shareholders to attend and vote for or against Resolution no.7 was 12,837,816,589; and
   4. the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil.
4. Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

- 4 -

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 7 and more than 75% of the total votes were cast in favour of Resolution no. 8, all Resolutions were duly passed as ordinary resolutions and special resolution (as applicable) of the Company.

By Order of the Board

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

ZHU Shunyan

Chairman and Chief Executive Officer

Hong Kong, July 30, 2020

As at the date of this announcement, the Board comprises eight Directors, of whom (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).

- 5 -